BAL 0891
Alternative Names: BAL-0891; TTK/PLK1 inhibitorLatest Information Update: 23 Jun 2025
At a glance
- Originator Netherlands Translational Research Center
- Developer Basilea Pharmaceutica; SillaJen Biotherapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors; Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Apr 2024 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 06 Oct 2023 Phase-I/II clinical trials in Solid tumours in USA (IV) (Crossfire Oncology pipeline, October 2023)